JP2006512314A - Ｊａｋインヒビターおよび他のプロテインキナーゼインヒビターとしての組成物の使用 - Google Patents

Ｊａｋインヒビターおよび他のプロテインキナーゼインヒビターとしての組成物の使用 Download PDF

Info

Publication number
JP2006512314A
JP2006512314A JP2004550434A JP2004550434A JP2006512314A JP 2006512314 A JP2006512314 A JP 2006512314A JP 2004550434 A JP2004550434 A JP 2004550434A JP 2004550434 A JP2004550434 A JP 2004550434A JP 2006512314 A JP2006512314 A JP 2006512314A
Authority
JP
Japan
Prior art keywords
compound
iii
ring
optionally substituted
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004550434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006512314A5 (https=
Inventor
マーク リードボー，
ブライアン レッドフォード，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2006512314A publication Critical patent/JP2006512314A/ja
Publication of JP2006512314A5 publication Critical patent/JP2006512314A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2004550434A 2002-11-01 2003-11-03 Ｊａｋインヒビターおよび他のプロテインキナーゼインヒビターとしての組成物の使用 Pending JP2006512314A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42297302P 2002-11-01 2002-11-01
PCT/US2003/034991 WO2004041789A1 (en) 2002-11-01 2003-11-03 Compositions useful as inhibitors of jak and other protein kinases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010140019A Division JP2010229154A (ja) 2002-11-01 2010-06-18 Ｊａｋインヒビターおよび他のプロテインキナーゼインヒビターとしての組成物の使用

Publications (2)

Publication Number Publication Date
JP2006512314A true JP2006512314A (ja) 2006-04-13
JP2006512314A5 JP2006512314A5 (https=) 2006-09-14

Family

ID=32312580

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004550434A Pending JP2006512314A (ja) 2002-11-01 2003-11-03 Ｊａｋインヒビターおよび他のプロテインキナーゼインヒビターとしての組成物の使用
JP2010140019A Pending JP2010229154A (ja) 2002-11-01 2010-06-18 Ｊａｋインヒビターおよび他のプロテインキナーゼインヒビターとしての組成物の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010140019A Pending JP2010229154A (ja) 2002-11-01 2010-06-18 Ｊａｋインヒビターおよび他のプロテインキナーゼインヒビターとしての組成物の使用

Country Status (8)

Country Link
US (1) US7312227B2 (https=)
EP (2) EP2172460A1 (https=)
JP (2) JP2006512314A (https=)
AT (1) ATE454378T1 (https=)
AU (2) AU2003286876A1 (https=)
CA (1) CA2506772A1 (https=)
DE (1) DE60330895D1 (https=)
WO (1) WO2004041789A1 (https=)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508107A (ja) * 2002-11-05 2006-03-09 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｊａｋおよび他のプロテインキナーゼのインヒビターとして有用な化合物
JP2006525991A (ja) * 2003-05-12 2006-11-16 ファイザー・プロダクツ・インク Ｐ２ｘ７受容体のベンズアミド阻害剤
JP2007500179A (ja) * 2003-07-30 2007-01-11 サイクラセル・リミテッド キナーゼ阻害剤としての２−アミノフェニル−４−フェニルピリミジン
JP2007508387A (ja) * 2003-10-16 2007-04-05 アボット・ラボラトリーズ バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するアミド
WO2009107391A1 (ja) * 2008-02-27 2009-09-03 武田薬品工業株式会社 ６員芳香環含有化合物
JP2009542680A (ja) * 2006-06-29 2009-12-03 キネックス ファーマシューティカルズ， エルエルシー キナーゼカスケードを調節するためのビアリル組成物および方法
JP2010520892A (ja) * 2007-03-12 2010-06-17 サイトピア・リサーチ・ピーティーワイ・リミテッド フェニルアミノピリミジン化合物およびその使用
JP2010538076A (ja) * 2007-09-04 2010-12-09 ザ スクリプス リサーチ インスティチュート タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン
US8598169B2 (en) 2004-12-28 2013-12-03 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
JP2014506908A (ja) * 2011-03-02 2014-03-20 リード ディスカバリー センター ゲーエムベーハー 薬学的活性化二置換ピリジン誘導体
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
US9926273B2 (en) 2012-08-30 2018-03-27 Athenex, Inc. Composition and methods for modulating a kinase cascade
USRE48285E1 (en) 2014-06-12 2020-10-27 Sierra Oncology, Inc. N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
JP2023544431A (ja) * 2020-10-09 2023-10-23 特科▲羅▼生物科技（成都）有限公司 Ｊａｋキナーゼ阻害剤としての小分子化合物及びその用途

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
AU2003262642B2 (en) * 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
WO2005012294A1 (en) 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
CA2545422C (en) * 2003-12-03 2015-06-02 Cytopia Research Pty Ltd Tubulin inhibitors
WO2006032851A1 (en) * 2004-09-20 2006-03-30 Biolipox Ab Pyrazole compounds useful in the treatment of inflammation
WO2006032852A1 (en) * 2004-09-20 2006-03-30 Biolipox Ab Pyrazole compounds useful uin the treatment of inflammation
JP2008515986A (ja) * 2004-10-13 2008-05-15 ワイス Ｎ−ベンゼンスルホニル置換アニリノ−ピリミジン類似物
SI1814878T1 (sl) 2004-11-24 2012-06-29 Rigel Pharmaceuticals Inc Spojine spiro-2,4-pirimidindiamina in njihova uporaba
ES2382068T3 (es) 2004-12-28 2012-06-05 Kinex Pharmaceuticals, Llc Composiciones y métodos para tratar trastornos de proliferación celular
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
EP1883302A4 (en) * 2005-05-03 2009-05-20 Rigel Pharmaceuticals Inc JAK KINASE HEMMER AND ITS USE
BRPI0610876B8 (pt) 2005-06-08 2021-05-25 Rigel Pharmaceuticals Inc composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP1940786B1 (en) 2005-09-16 2010-08-18 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
EP1943234A1 (en) * 2005-10-31 2008-07-16 Biolipox AB Triazole compounds as lipoxygenase inhibitors
JP2009513692A (ja) * 2005-11-01 2009-04-02 バイオリポックス エービー 炎症の治療に有用なピラゾール化合物
KR20080110998A (ko) * 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
ES2622493T3 (es) * 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
US7834178B2 (en) * 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
JP5161233B2 (ja) 2006-10-19 2013-03-13 ライジェル ファーマシューティカルズ， インコーポレイテッド 自己免疫疾患の処置のためのｊａｋキナーゼの阻害剤としての２，４−ピリミジンアミン誘導体
US20080153822A1 (en) * 2006-11-30 2008-06-26 Martin Augustin Methods of treating pain
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
AU2013201306B2 (en) * 2007-03-12 2015-11-12 Glaxosmithkline Llc Phenyl Amino Pyrimidine Compounds and Uses Thereof
AU2016200866B2 (en) * 2007-03-12 2017-06-22 Glaxosmithkline Llc Phenyl amino pyrimidine compounds and uses thereof
EP2155194B1 (en) 2007-04-06 2015-01-21 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
CL2008000986A1 (es) 2007-04-06 2008-10-17 Neurocrine Biosciences Inc COMPUESTO DERIVADO DE HETEROCICLOS DE NITROGENO, AGONISTAS DEL RECEPTOR GnRH; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHO COMPUESTO; Y USO PARA TRATAR UNA AFECCION RELACIONADA CON LAS HORMONAS SEXUALES, ENDOMETRIOSIS, DISMENORREA, ENFERMEDAD DE OV
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
WO2009029998A1 (en) * 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
WO2009034390A1 (en) * 2007-09-14 2009-03-19 Arrow Therapeutics Limited Heterocyclic derivatives and their use in treating hepatitis c
AU2008335709A1 (en) * 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
HUE030912T2 (en) 2008-02-15 2017-06-28 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US8063058B2 (en) 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
AU2009238590A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
MX353308B (es) 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
CN106420756A (zh) * 2009-07-28 2017-02-22 里格尔药品股份有限公司 抑制jak途径的组合物和方法
WO2011129936A2 (en) 2010-04-16 2011-10-20 Kinex Pharmaceuticals, Llc Compositions and methods for the prevention and treatment of cancer
EP2975027A1 (en) 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
WO2012066065A1 (en) * 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
MX363551B (es) 2011-11-23 2019-03-27 Portola Pharmaceuticals Inc Star Compuestos derivados de pirazina como inhibidores de cinasa.
MX371331B (es) 2012-04-24 2020-01-27 Vertex Pharma Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
RU2015107550A (ru) * 2012-08-23 2016-10-10 Ф. Хоффманн-Ля Рош Аг Новые фенилпиридин/пиразинамиды для лечения рака
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
WO2014070978A1 (en) 2012-11-03 2014-05-08 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
ME03336B (me) 2013-03-12 2019-10-20 Vertex Pharma Inhibitori dnk-pk
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
JP6408569B2 (ja) 2013-10-17 2018-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2015108861A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
EP3518931A4 (en) 2016-09-27 2020-05-13 Vertex Pharmaceuticals Incorporated METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
CN108503583B (zh) * 2018-05-14 2020-10-09 江南大学 一种含氮氢类化合物的烷基化方法及其应用
US12208098B2 (en) * 2018-11-26 2025-01-28 Gachon University Of Industry-Academic Cooperation Foundation 4-carbonylamino-4-phenylpyrimidine compound or pharmaceutically acceptable salt thereof
KR102540219B1 (ko) * 2018-11-26 2023-06-08 (의료)길의료재단 신규한 4-카보닐아미노-4-페닐피리미딘 화합물 또는 이의 약제학적으로 허용가능한 염
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
EP3955920A1 (en) 2019-04-16 2022-02-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
CN110330484B (zh) * 2019-07-18 2022-08-26 中国药科大学 取代类苯基嘧啶衍生物作为jak激酶抑制剂或其可药用的盐、制备方法及用途
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
CN120157658B (zh) * 2025-03-07 2026-01-09 辽宁大学 含有甲苯结构的氨基嘧啶类化合物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019065A1 (en) * 1995-11-20 1997-05-29 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
WO2002046170A2 (en) * 2000-12-06 2002-06-13 Signal Pharmaceuticals, Inc. Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
WO2002046171A2 (en) * 2000-12-06 2002-06-13 Signal Pharmaceuticals, Inc. Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
WO2002079197A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
WO1995009851A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
WO1995009847A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pyrimidineamine derivatives and processes for the preparation thereof
PT672041E (pt) 1993-10-01 2002-04-29 Novartis Ag Derivados da piridina farmacologicamente activos e processos para a sua preparacao
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
AU9502601A (en) * 2000-09-06 2002-03-22 Chiron Corp Inhibitors of glycogen synthase kinase 3
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB0107901D0 (en) 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
EP1560824A1 (en) * 2002-11-05 2005-08-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019065A1 (en) * 1995-11-20 1997-05-29 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
WO2002046170A2 (en) * 2000-12-06 2002-06-13 Signal Pharmaceuticals, Inc. Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
WO2002046171A2 (en) * 2000-12-06 2002-06-13 Signal Pharmaceuticals, Inc. Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
WO2002079197A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508107A (ja) * 2002-11-05 2006-03-09 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｊａｋおよび他のプロテインキナーゼのインヒビターとして有用な化合物
JP2006525991A (ja) * 2003-05-12 2006-11-16 ファイザー・プロダクツ・インク Ｐ２ｘ７受容体のベンズアミド阻害剤
JP2007500179A (ja) * 2003-07-30 2007-01-11 サイクラセル・リミテッド キナーゼ阻害剤としての２−アミノフェニル−４−フェニルピリミジン
JP2007508387A (ja) * 2003-10-16 2007-04-05 アボット・ラボラトリーズ バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するアミド
US9580387B2 (en) 2004-12-28 2017-02-28 Athenex, Inc. Biaryl compositions and methods for modulating a kinase cascade
US8598169B2 (en) 2004-12-28 2013-12-03 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
JP2009542680A (ja) * 2006-06-29 2009-12-03 キネックス ファーマシューティカルズ， エルエルシー キナーゼカスケードを調節するためのビアリル組成物および方法
JP2010520892A (ja) * 2007-03-12 2010-06-17 サイトピア・リサーチ・ピーティーワイ・リミテッド フェニルアミノピリミジン化合物およびその使用
US9233934B2 (en) 2007-03-12 2016-01-12 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
JP2014114311A (ja) * 2007-03-12 2014-06-26 Ym Biosciences Australia Pty Ltd フェニルアミノピリミジン化合物およびその使用
US12570614B2 (en) 2007-03-12 2026-03-10 Glaxosmith Kline Llc Phenyl amino pyrimidine compounds and uses thereof
JP2016175934A (ja) * 2007-03-12 2016-10-06 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド フェニルアミノピリミジン化合物およびその使用
US9238628B2 (en) 2007-03-12 2016-01-19 YM Biosicences Australia PTY LTD Phenyl amino pyrimidine compounds and uses thereof
JP2015145386A (ja) * 2007-03-12 2015-08-13 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド フェニルアミノピリミジン化合物およびその使用
US10196357B2 (en) 2007-04-13 2019-02-05 Athenex, Inc. Biaryl compositions and methods for modulating a kinase cascade
JP2010538076A (ja) * 2007-09-04 2010-12-09 ザ スクリプス リサーチ インスティチュート タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン
JP2015007102A (ja) * 2007-09-04 2015-01-15 ザ スクリプス リサーチ インスティテュート タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン
US9018205B2 (en) 2007-09-04 2015-04-28 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009107391A1 (ja) * 2008-02-27 2009-09-03 武田薬品工業株式会社 ６員芳香環含有化合物
JP2014506908A (ja) * 2011-03-02 2014-03-20 リード ディスカバリー センター ゲーエムベーハー 薬学的活性化二置換ピリジン誘導体
US9242937B2 (en) 2011-03-02 2016-01-26 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted pyridine derivatives
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
US10106505B2 (en) 2012-08-30 2018-10-23 Athenex, Inc. Composition and methods for modulating a kinase cascade
US9926273B2 (en) 2012-08-30 2018-03-27 Athenex, Inc. Composition and methods for modulating a kinase cascade
USRE48285E1 (en) 2014-06-12 2020-10-27 Sierra Oncology, Inc. N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
USRE49445E1 (en) 2014-06-12 2023-03-07 Sierra Oncology, Inc. N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
USRE50497E1 (en) 2014-06-12 2025-07-22 Glaxosmithkline Llc (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
JP2023544431A (ja) * 2020-10-09 2023-10-23 特科▲羅▼生物科技（成都）有限公司 Ｊａｋキナーゼ阻害剤としての小分子化合物及びその用途
JP7587886B2 (ja) 2020-10-09 2024-11-21 特科▲羅▼生物科技（成都）有限公司 Ｊａｋキナーゼ阻害剤としての小分子化合物及びその用途

Also Published As

Publication number Publication date
WO2004041789A1 (en) 2004-05-21
AU2003286876A1 (en) 2004-06-07
US20040147507A1 (en) 2004-07-29
US7312227B2 (en) 2007-12-25
CA2506772A1 (en) 2004-05-21
JP2010229154A (ja) 2010-10-14
AU2011200057A1 (en) 2011-01-27
ATE454378T1 (de) 2010-01-15
DE60330895D1 (de) 2010-02-25
EP1562911B1 (en) 2010-01-06
EP1562911A1 (en) 2005-08-17
EP2172460A1 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
JP2006512314A (ja) Ｊａｋインヒビターおよび他のプロテインキナーゼインヒビターとしての組成物の使用
JP4688498B2 (ja) Ｊａｋインヒビターとしてのヘテロアリール−ピリミジン誘導体
JP4741948B2 (ja) プロテインキナーゼインヒビターおよびそれらの使用
DE60214701T2 (de) Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen
CA2507406A1 (en) Compounds useful as inhibitors of jak and other protein kinases
CA2487679A1 (en) Inhibitors of jak and cdk2 protein kinases
EP1697375A2 (en) Heterocyclic protein kinase inhibitors and uses thereof
CA2900012A1 (en) Erk inhibitors and uses thereof
EP1610793A2 (en) Thiazoles useful as inhibitors of protein kinases
MXPA05005477A (es) Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
KR20070095952A (ko) 염증성 질환, 증식성 질환 및 면역학적으로 매개된 질환치료용 Ｔｅｃ 계열 단백질 키나제의 억제제로서 유용한피리드-2-온
JP2006520386A (ja) プロテインキナーゼインヒビターとして有用な組成物
CN101495474A (zh) 可用作蛋白激酶抑制剂的噻吩-甲酰胺类
EP2243781A1 (en) Pyrazolopyridine derivatives as inhibitors of JAK and CDK2 protein kinases

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20060720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100317

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100416

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100517

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100728